Evidence map›Paper›PMID 21160595›Full record

ArticleWorld journal of gastrointestinal oncology2010

Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond.

Angelo Zullo, Cesare Hassan, Francesca Cristofari, Francesco Perri, Sergio Morini

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastrointestinal oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Development and evaluation of a double-check support system using artificial intelligence in endoscopic screening for gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Article
  4. Gastrointestinal lymphoma: the new mimic.BMJ open gastroenterology · 2019
    Review
  5. Article
  6. Article
  7. Article
  8. Rare gastrointestinal lymphomas: The endoscopic investigation.World journal of gastrointestinal endoscopy · 2015
    Review
  9. Review
  10. Gastric MALT lymphoma: old and new insights.Annals of gastroenterology · 2014
    Review
  11. Review
  12. Helicobacter pylori therapy: Present and future.World journal of gastrointestinal pharmacology and therapeutics · 2012
    Article
  13. Article
  14. Article
  15. Article
  16. MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012
    Article
  17. Lack of association of conjunctival MALT lymphoma with Chlamydiae or Helicobacter pylori in a cohort of Chinese patients.Medical science monitor : international medical journal of experimental and clinical research · 2012
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Angelo ZulloAngelo Zullo, Cesare Hassan, Francesca Cristofari, Sergio Morini, Gastroenterology and Digestive Endoscopy, "Nuovo Regina Margherita" Hospital, 00153 Roma, Italy.
Cesare Hassan
Francesca Cristofari
Francesco Perri
Sergio Morini
Ospedale Regina Margherita · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The stomach is the most frequently involved site for extranodal lymphomas, accounting for nearly two-thirds of all gastrointestinal cases. It is widely accepted that gastric B-cell, low-grade mucosal-associated lymphoid tissue (MALT)-lymphoma is caused by Helicobacter pylori (H. pylori) infection. MALT-lymphomas may engender different clinical and endoscopic patterns. Often, diagnosis is confirmed in patients with only vague dyspeptic symptoms and without macroscopic lesions on gastric mucosa. H. pylori eradication leads to lymphoma remission in a large number of patients when treatment occurs at an early stage (I-II(1)). Neoplasia confined to the submucosa, localized in the antral region of the stomach, and without API2-MALT1 translocation, shows a high probability of remission following H. pylori eradication. When both bacterial infection and lymphoma recur, further eradication therapy is generally effective. Radiotherapy, chemotherapy and, in selected cases, surgery are the available therapeutic options with a high success rate for those patients who fail to achieve remission, while data on immunotherapy with monoclonal antibodies (rituximab) are still scarce. The 5-year survival rate is higher than 90%, but careful, long-term follow-up is required in these patients since lymphoma recurrence has been reported in some cases.

Indexed as

Clinical presentationEndoscopyGastric lymphomaHelicobacter pyloriMucosal-associated lymphoid tissuePredictive factorsTherapy

Identifiers

PMID21160595
PMCPMC2998825
OpenAlexW2056438694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.